UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/613,749	07/03/2003	Arthur M. Krieg	C1037.70041US00	6452
23628 7590 08/20/2008 WOLF GREENFIELD & SACKS, P.C.			EXAMINER	
600 ATLANTIC	C AVENUE	•	MINNIFIELD, NITA M	
BOSTON, MA 02210-2206			ART UNIT	PAPER NUMBER
			1645	
			MAIL DATE	DELIVERY MODE
			08/20/2008	PAPER
			00/20/2008	FAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/613,749	KRIEG, ARTHUR M.				
Office Action Summary	Examiner	Art Unit				
	N. M. Minnifield	1645				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 16 Ma	av 2008					
·= · ·						
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>See Continuation Sheet</u> is/are pending in the application.						
4a) Of the above claim(s) <u>5,13,15,48-52,56,57,65 and 66</u> is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>See Continuation Sheet</u> is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>95</u> are subject to restriction and/or ele	ction requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date Notice of Informal Patent Application						
Paper No(s)/Mail Date 6) Other:						

Continuation of Disposition of Claims: Claims pending in the application are 1-5,8-15,19-21,23,28-33,44,46,47,53-55,58,64,71-74,77-81,84,85,89,90,95,96,98 and 100-105.

Continuation of Disposition of Claims: Claims allowed are 1-4,8-12,19-21,23,28-33,44,46,47,53-55,58,64,71-74,77-81,84,85,89,90,96,98 and 100-105.

Application/Control Number: 10/613,749 Page 2

Art Unit: 1645

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 16, 2008 has been entered.

Response to Amendment

- 2. Applicant's amendment filed May 16, 2008 is acknowledged and has been entered. Claims 6, 7, 16-18, 22, 24-27, 34-43, 45, 59-63, 67-70, 75, 76, 82, 83, 86-88, 91-94, 97 and 99 have been canceled. Claims 1-5, 8-15, 19-21, 23, 28-33, 44, 46, 47, 53-55, 58, 64, 71-74, 77-81, 84, 85, 89, 90, 95, 96, 98 and 100-105 are now pending in the present application. All rejections have been withdrawn in view of Applicants' amendment to the claims and/or comments, with the exception of those discussed below.
- 3. This application contains claims 5, 13, 15, 48-52, 56, 57, 65 and 66 are drawn to an invention and/or species nonelected with traverse in paper filed July 25, 2007. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Application/Control Number: 10/613,749

Art Unit: 1645

4. Claims 1-4, 8-12, 14, 19-21, 23, 28-33, 44, 46, 47, 53-55, 58, 64, 71-74, 77-81, 84, 85, 89, 90, 95, 96, 98 and 100-105 are allowable with regard to the elected species lung cancer.

Page 3

Election/Restrictions

5. This application contains claims directed to the following patentably distinct species: The claims recite multiple species (microbial antigen, cancer antigen and allergen; see claims 4 and 55) of the genus antigen as well as multiple sub-species of the microbial antigen (bacterial antigen, viral antigen (specific viral antigens, see claims 49 and 56), fungal antigen, parasitic antigen; see claim 5) and cancer antigen (see claim 95).

Applicant has previously elected the species of cancer, specifically lung cancer. Applicant is requested to elect another specific cancer for examination with regard to claim 95. The species are independent and distinct because the various types of cancers recited in claim 95 are structurally and functionally independent and distinct.

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

There is an examination and search burden for these patentably distinct species due to their mutually exclusive characteristics. The species require a different field of search (e.g., searching different classes/subclasses or electronic

Art Unit: 1645

resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another species; and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Application/Control Number: 10/613,749 Page 5

Art Unit: 1645

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 571-272-0860. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-8975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/N. M. Minnifield/ Primary Examiner, Art Unit 1645 August 17, 2008